Oncology Sciences Corp.
This article was originally published in Start Up
Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.
You may also be interested in...
Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)